Celero Systems Inc. reported details of a patent filing for gastric residency systems for its ingestible devices, in the form a plurality of retention arms with non-deployed and deployed states sized and configured to temporarily retain the ingestible devices in the stomach for periods of up to a week.

PERTH, Australia – Atmo Biosciences Ltd. has closed an oversubscribed AU$9.6 million (US$7 million) capital raise that will allow it to further develop its gas-sensing capsule for monitoring the health of the gut and the microbiome. Until now, there has not been a diagnostic test that can measure gases in the gut in vivo.